Caxton Associates LP Has $567,000 Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

Caxton Associates LP cut its position in Fate Therapeutics, Inc. (NASDAQ:FATE) by 40.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 172,863 shares of the biopharmaceutical company’s stock after selling 117,324 shares during the period. Caxton Associates LP’s holdings in Fate Therapeutics were worth $567,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Ausdal Financial Partners Inc. acquired a new position in shares of Fate Therapeutics in the 2nd quarter valued at $33,000. Victory Capital Management Inc. lifted its holdings in Fate Therapeutics by 22.8% during the fourth quarter. Victory Capital Management Inc. now owns 12,504 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 2,322 shares in the last quarter. DRW Securities LLC acquired a new position in Fate Therapeutics in the second quarter valued at about $71,000. Arizona State Retirement System bought a new stake in shares of Fate Therapeutics in the second quarter worth about $84,000. Finally, Headlands Technologies LLC raised its position in shares of Fate Therapeutics by 5,258.6% during the second quarter. Headlands Technologies LLC now owns 28,508 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 27,976 shares during the period. 97.54% of the stock is currently owned by institutional investors and hedge funds.

Fate Therapeutics Price Performance

Fate Therapeutics stock opened at $3.50 on Friday. The firm has a 50-day moving average of $3.98 and a 200-day moving average of $4.45. The company has a market cap of $398.41 million, a price-to-earnings ratio of -1.82 and a beta of 1.84. Fate Therapeutics, Inc. has a one year low of $1.63 and a one year high of $8.83.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.14. Fate Therapeutics had a negative return on equity of 44.09% and a negative net margin of 1,426.67%. The firm had revenue of $6.77 million during the quarter, compared to the consensus estimate of $1.47 million. As a group, sell-side analysts expect that Fate Therapeutics, Inc. will post -1.73 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on FATE shares. HC Wainwright reiterated a “neutral” rating and issued a $5.00 price objective on shares of Fate Therapeutics in a research report on Thursday, August 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Fate Therapeutics in a research note on Wednesday, August 14th. Finally, Piper Sandler raised shares of Fate Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $4.00 to $6.00 in a research report on Monday, June 17th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $6.90.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.